The FDA has cleared for marketing a test that could help predict risk for coronary heart disease events in people with no history of heart disease. The PLAC Test for Lp-PLA2 Activity assesses the level of serum lipoprotein-associated phospholipase A2 (Lp-PLA2) — a marker of vascular inflammation.
Researchers used the test to measure Lp-PLA2 levels in 4600 people aged 45 to 92 who were free of CHD at baseline. After a median follow-up of 5 years, people with Lp-PLA2 levels above 225 nmol/min/mL had a higher rate of CHD events than those with lower levels (7.0% vs. 3.3%). The FDA said that the test predicts risk most accurately in black women.
FDA news release